BRCA Initiative Meeting

BRCA germline mutations are approximately 10 times more prevalent in Israel than in the general population. This increased prevalence provides a unique opportunity to study BRCA-associated cancers such as breast, ovarian, prostate, endometrial, and pancreatic cancers.

About the initiative

The RTICC (Technion) and the Broad Institute of MIT and Harvard are initiating a research consortium that will unite researchers from both institutions, as well as other partner institutions, combining Israel's unique genetic diversity and patient population with cutting-edge multi-omics and spatial technologies, as well as basic science and engineering (e.g., biology, mathematics, computer science, physics, chemistry).

The collaboration aims to create a shared platform that fosters cooperation, maximizes resources, and addresses critical questions in BRCA-related and homologous recombination (HRD)-related cancers.